SCHEMBL30066697

SCHEMBL30066697

CC(C(N)=O)c1ncncn1

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.36
HSP90AA1 P07900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28670536 0.80 PTGS2 (0.36)
SCHEMBL1483488 0.80 EPHX1 (0.37) EPHX1
SCHEMBL27860662 0.74 HSP90AA1 (0.33) HSP90AA1
Isobutyramide SCHEMBL28204789 0.72 LMNA (0.33) EPHX1HSP90AA1
Carbamic Acid SCHEMBL3906037 0.70 HCAR3 (0.34)
SCHEMBL1484347 0.70 EPHX1 (0.44) EPHX1
SCHEMBL16370195 0.68 SCN10A (0.38)
SCHEMBL2492017 0.67 CTSD (0.43) EPHX1
SCHEMBL19273295 0.66
SCHEMBL1838866 0.65 ADORA3 (0.47) HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4543455-A2 METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY Enalare Therapeutics Inc. (US) 2025-04-30 EP disclosed
EP-4504206-A2 RESPIRATORY STIMULANT NASAL FORMULATIONS Enalare Therapeutics Inc. (US) 2025-02-12 EP disclosed
EP-4426308-A1 METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT Enalare Therapeutics Inc. (US) 2024-09-11 EP disclosed
EP-4333852-A1 LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF Enalare Therapeutics Inc. (US) 2024-03-13 EP disclosed
WO-2023250141-A2 METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY ENALARE THERAPEUTICS INC. (US) 2023-12-28 WO disclosed
WO-2023192602-A2 RESPIRATORY STIMULANT NASAL FORMULATIONS ENALARE THERAPEUTICS INC. (US) 2023-10-05 WO disclosed
WO-2023081185-A1 METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT ENALARE THERAPEUTICS INC. (US) 2023-05-11 WO disclosed
WO-2022235771-A1 LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF ENALARE THERAPEUTICS INC. (US) 2022-11-10 WO disclosed